Epclusa is an anti-hepatitis C drug owned by Gilead Sciences Inc. The drug contains Sofosbuvir and Velpatasvir as active ingredients. Epclusa was first authorized for market use on June 28, 2016. The drug holds a total of 32 patents.
The generic version of Epclusa is anticipated to become available after July 30, 2034. This generic release date is projected based on the expiration date of the last Epclusa-related patent which expires on the said date.
Epclusa is primarily used for the treatment of hepatitis C. Its active ingredients, Sofosbuvir and Velpatasvir, work in combination to stop the virus from multiplying in the body
Epclusa holds 32 patents in total. The most relevant patents to the Epclusa generic availability are those expiring in 2034. These patents are titled 'Combination formulation of two antiviral compounds.' Below are the details of the patent: